Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2014

01-04-2014 | Original Article

Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation

Authors: Masatoshi Sakurai, Takehiko Mori, Jun Kato, Yuya Koda, Taku Kikuchi, Sumiko Kohashi, Masuho Saburi, Takaaki Toyama, Yoshinobu Aisa, Tomonori Nakazato, Noriko Beppu, Soichiro Tsuda, Naoyuki Shigematsu, Shinichiro Okamoto

Published in: International Journal of Hematology | Issue 4/2014

Login to get access

Abstract

High-dose melphalan has been gaining recognition as a highly emetogenic agent used in hematopoietic stem cell transplantation (HSCT). The aim of this retrospective study was to elucidate the efficacy of aprepitant in preventing high-dose melphalan-induced emesis. Sixty patients who received melphalan (70 mg/m2/day, 2 days) and fludarabine (125 mg/m2/day, 5 days) as conditioning for allogeneic HSCT for hematological malignancies, and who received ondansetron and methylprednisolone as an antiemetic prophylaxis, were eligible. Twenty of these 60 patients also received aprepitant for 5 days (aprepitant group); the remaining 40 patients served as a control. The rates of complete response (CR), defined as no emesis without rescue medications, and complete protection (CP), defined as no emesis with or without rescue medications, were assessed between the two groups. The observation period was 12 days from the first day of melphalan administration. The CR and CP rates were significantly higher in the aprepitant group than in the control group during the observation period (35 % versus 10 %, P < 0.05; 85 % versus 33 %, P < 0.001; respectively). These results suggest that aprepitant in combination with ondansetron and steroid effectively ameliorates nausea and vomiting caused by the high-dose melphalan-based conditioning for allogeneic HSCT.
Literature
1.
Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987;66:55–62.PubMedCrossRef
2.
Maraninchi D, Abecasis M, Gastaut JA, Sebahoun G, Cahn JY, Hervé P, et al. High-dose melphalan and autologous bone marrow transplant for relapsed acute leukaemia. Cancer Chemother Pharmacol. 1983;10:109–11.PubMedCrossRef
3.
Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis. J Natl Compr Canc Netw. 2007;5:12–33.PubMed
4.
Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57:191–8.PubMedCrossRef
5.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(Suppl 5):v232–43.PubMedCrossRef
6.
Basch E, Hesketh PJ, Kris MG, Prestrud AA, Temin S, Lyman GH. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2011;7:395–8.PubMedCentralPubMedCrossRef
7.
Martino R, Caballero MD, Canals C, Simón JA, Solano C, Urbano-Ispízua A, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001;115:653–9.PubMedCrossRef
8.
Viner CV, Selby PJ, Zulian GB, Gore ME, Butcher ME, Wootton CM, et al. Ondansetron—a new safe and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemother Pharmacol. 1990;25:449–53.PubMedCrossRef
9.
Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 2011;22:939–46.PubMedCrossRef
10.
Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract. 2010;16:45–51.PubMedCrossRef
11.
Pielichowski W, Barzal J, Gawronski K, Mlot B, Oborska S, Wasko-Grabowska A, et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc. 2011;43:3107–10.PubMedCrossRef
12.
Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011;46:784–9.PubMedCrossRef
13.
Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer. 2012;20:3141–8.PubMedCrossRef
14.
Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplant. 2008;42:501–6.PubMedCrossRef
15.
Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant. 2013;19(49–55):e1.PubMed
16.
Uchida M, Kato K, Ikesue H, Ichinose K, Hiraiwa H, Sakurai A, et al. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy. 2013;33:893–901.PubMedCentralPubMedCrossRef
17.
Kameoka Y, Takahashi N, Ishizawa K, Kato Y, Ito J, Sasaki O, et al. Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. Int J Hematol. 2012;96:624–30.PubMedCrossRef
18.
Roila F, Warr D, Aapro M, Clark-Snow RA, Einhorn L, Gralla RJ, et al. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Cancer. 2011;19(Suppl 1):S57–62.PubMedCrossRef
19.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–9.PubMedCrossRef
20.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–8.PubMedCrossRef
21.
Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000–6.PubMedCrossRef
22.
de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004;40:403–10.PubMedCrossRef
23.
Feyer PC, Maranzano E, Molassiotis A, Roila F, Clark-Snow RA, Jordan K. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer. 2011;19(Suppl 1):S5–14.PubMedCrossRef
24.
Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K, et al. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant. 2001;28:1061–6.PubMedCrossRef
25.
Nakade S, Ohno T, Kitagawa J, Hashimoto Y, Katayama M, Awata H, et al. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2008;63:75–83.PubMedCrossRef
26.
McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17–24.PubMedCrossRef
27.
de Jonge ME, Huitema AD, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005;56:370–8.PubMedCrossRef
28.
Egerer G, Eisenlohr K, Gronkowski M, Burhenne J, Riedel KD, Mikus G. The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol. 2010;70:903–7.PubMedCentralPubMedCrossRef
Metadata
Title
Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation
Authors
Masatoshi Sakurai
Takehiko Mori
Jun Kato
Yuya Koda
Taku Kikuchi
Sumiko Kohashi
Masuho Saburi
Takaaki Toyama
Yoshinobu Aisa
Tomonori Nakazato
Noriko Beppu
Soichiro Tsuda
Naoyuki Shigematsu
Shinichiro Okamoto
Publication date
01-04-2014
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-014-1538-6

Other articles of this Issue 4/2014

International Journal of Hematology 4/2014 Go to the issue

Original Article

Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients

Progress in Hematology

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

Progress in Hematology

Progress towards gene therapy for haemophilia B

Case Report

Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status

Original Article

Nov/CCN3 regulates long-term repopulating activity of murine hematopoietic stem cells via integrin αvβ3

Case Report

Primary bone marrow Hodgkin lymphoma in an HIV-negative patient
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits